Chronic myeloid leukemia BCR/ABL1 mutation clonal evolution and treatment strategies / 中华检验医学杂志

ABSTRACT

Application of imatinib has made a lot of chronic myeloid leukemia (CML) patients longterm survival,but the CML BCR/ABL1 kinase domain mutations (KDM) will result in drug resistance of imatinib.There are many KDM types.The different types appear randomly.The leukemic clone with different KDM characteristics has a certain evolution.In the period of imatinib treatment,a higher degree of drug resistance mutations in cells likely to develop as the dominant clone.It is suggested that the treatment of imatinib-resistant CML in addition to efforts to develop next-generation tyrosine kinase inhibitors outside,but also consider the use of traditional medicine to help cure.